Generic placeholder image

Current Pharmaceutical Analysis

Author(s): Shuchen Pei, Junlin Chen, Shihao Xia, Jieyu Wang, Buyin Xue, Qunliang Wang and Jun Chen*

DOI: 10.2174/1573412916666200120144817

DownloadDownload PDF Flyer Cite As
Identification, Isolation and Characterization of a Pharmaceutical Impurity in Levocetirizine Hydrochloride

Page: [624 - 628] Pages: 5

  • * (Excluding Mailing and Handling)

Abstract

Background: Levocetirizine is chemically know as (R)-(-)-2-[4-(4-chlorobenzhydryl)-1- piperazinyl]-ethoxy acetic acid dihydrochloride. Many publications have reported the synthetic routes of levocetirizine. Several related substances have been detected in levocetirizine hydrochloride drug substances. In our study, a pharmaceutical impurity, at the level of >0.1% w/w, was isolated, purified and identified. It is not included in the European Pharmacopoeia (EP).

Objective: Identification, isolation and characterization of a new pharmaceutical impurity in levocetirizine hydrochloride.

Methods: The impurity was enriched by normal phase silica gel, and was further purified by semipreparative HPLC. It was separated from the crystallization mother liquor of levocetirizine hydrochloride for the first time. Mass spectrometry and nuclear magnetic resonance spectroscopy are the ultimate tools in structure elucidation.

Results: The structure was identified as levocetirizine quaternary ammonium. The formation mechanisms of the impurity are also presented. The method was applied to the determination of the impurity in levocetirizine hydrochloride in real samples.

Conclusion: The method was applied to the determination the impurity of levocetirizine hydrochloride in real samples.

Keywords: Levocetirizine hydrochloride, API, impurity, isolation, semipreparation, structural identification.

Graphical Abstract

[1]
Siddiqui, M.R.; Alothman, Z.A.; Rahman, N. Analytical techniques in pharmaceutical analysis: A review. Arab. J. Chem., 2017, 10(S1), S1409-S1421.
[http://dx.doi.org/10.1016/j.arabjc.2013.04.016]
[2]
Alothman, Z.A.; Rahman, N.; Siddiqui, M.R. Review on pharmaceutical impurities, stability studies and degradation products: an analytical approach. Rev. Adv. Sci. Eng., 2013, 2(2), 155-166.
[http://dx.doi.org/10.1166/rase.2013.1039]
[3]
Rahman, N.; Azmi, S.N.H.; Wu, H.F. The importance of impurity analysis in pharmaceutical products: an integrated approach. Accredit. Qual. Assur., 2006, 11(1-2), 69-74.
[http://dx.doi.org/10.1007/s00769-006-0095-y]
[4]
ICH Steering Committee. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use-Impurities in new drug substances. ICH Steering Committee , . 2002.
[5]
Chen, C. Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Curr. Med. Chem., 2008, 15(21), 2173-2191.
[http://dx.doi.org/10.2174/092986708785747625]
[6]
De Vos, C.; Maleux, M.R.; Baltes, E.; Gobert, J. Inhibition of histamine and allergen skin wheal by cetirizine in four animal species. Ann. Allergy, 1987, 59(4), 278-282.
[PMID: 2959177]
[7]
Tzanetos, D.B.; Fahrenholz, J.M.; Scott, T.; Buchholz, K. Comparison of the sedating effects of levocetirizine and cetirizine: a randomized, double-blind, placebo-controlled trial. Ann. Allergy Asthma Immunol., 2011, 107(6), 517-522.
[http://dx.doi.org/10.1016/j.anai.2011.08.012] [PMID: 22123381]
[8]
Hair, P.I.; Scott, L.J. Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies. Drugs, 2006, 66(7), 973-996.
[http://dx.doi.org/10.2165/00003495-200666070-00017] [PMID: 16740020]
[9]
Gillard, M.; Van Der Perren, C.; Moguilevsky, N.; Massingham, R.; Chatelain, P. Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). Mol. Pharmacol., 2002, 61(2), 391-399.
[http://dx.doi.org/10.1124/mol.61.2.391] [PMID: 11809864]
[10]
Wang, D.Y.; Hanotte, F.; De Vos, C.; Clement, P. Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine-induced nasal response in healthy adult volunteers. Allergy, 2001, 56(4), 339-343.
[http://dx.doi.org/10.1034/j.1398-9995.2001.00775.x] [PMID: 11284803]
[11]
Potter, P.C. Study Group. Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites. Allergy, 2003, 58(9), 893-899.
[http://dx.doi.org/10.1034/j.1398-9995.2003.00171.x] [PMID: 12911418]
[12]
Bousquet, J.; Demarteau, N.; Mullol, J.; van den Akker-van Marle, M.E.; Van Ganse, E.; Bachert, C. XPERT study group. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. Allergy, 2005, 60(6), 788-794.
[http://dx.doi.org/10.1111/j.1398-9995.2005.00820.x] [PMID: 15876309]
[13]
Deruaz, C.; Leimgruber, A.; Berney, M.; Pradervand, E.; Spertini, F. Levocetirizine better protects than desloratadine in a nasal provocation with allergen. J. Allergy Clin. Immunol., 2004, 113(4), 669-676.
[http://dx.doi.org/10.1016/j.jaci.2004.01.773] [PMID: 15100671]
[14]
Ghislieri, D.; Green, A.P.; Pontini, M.; Willies, S.C.; Rowles, I.; Frank, A.; Grogan, G.; Turner, N.J. Engineering an enantioselective amine oxidase for the synthesis of pharmaceutical building blocks and alkaloid natural products. J. Am. Chem. Soc., 2013, 135(29), 10863-10869.
[http://dx.doi.org/10.1021/ja4051235] [PMID: 23808566]
[15]
Wang, L.; Wang, T.; Yang, B. Design, synthesis, and anti-allergic activities of novel (R)(-)-1-[(4-chlorophenyl)phenyl methyl]piperazine derivatives. Med. Chem. Res., 2010, 21(1), 124-132.
[http://dx.doi.org/10.1007/s00044-010-9512-1]
[16]
Santhoshi, A.; Kumar, S.N.; Sujitha, P. Synthesis of 1-benzhydryl piperazine derivatives and evaluation of their ACE inhibition and antimicrobial activities. Med. Chem. Res., 2014, 23(6), 3207-3219.
[http://dx.doi.org/10.1007/s00044-013-0895-7]
[17]
EDQM. European Pharmacopoeia, 8th ed; Council of Europe: Germany, 2013, pp. 1831-1833.
[18]
Wang, S.Z.; Zhao, Y.F.; Sun, J.Y.; Guo, X.J. Determination of enantiomeric impurity in levocetirizine tablets by capillary electrophoresis. Zhejiang Da Xue Xue Bao Yi Xue Ban, 2014, 43(2), 150-154.
[PMID: 24782369]